Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ARN
|
|||
| Former ID |
DIB010453
|
|||
| Drug Name |
SAR-125844
|
|||
| Synonyms |
Met inhibitor (iv, cancer), sanofi-aventis
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
Sanofi
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H23FN8O2S2
|
|||
| Canonical SMILES |
C1COCCN1CCNC(=O)NC2=NC3=C(S2)C=C(C=C3)SC4=NN=C5N4N=C(C=C5)C6=CC=C(C=C6)F
|
|||
| InChI |
1S/C25H23FN8O2S2/c26-17-3-1-16(2-4-17)19-7-8-22-30-31-25(34(22)32-19)37-18-5-6-20-21(15-18)38-24(28-20)29-23(35)27-9-10-33-11-13-36-14-12-33/h1-8,15H,9-14H2,(H2,27,28,29,35)
|
|||
| InChIKey |
ODIUNTQOXRXOIV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1116743-46-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02435121) A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification. U.S. National Institutes of Health. | |||
| REF 2 | The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.